The Hospital Group operates a network of more than 20 clinics around the United Kingdom and Ireland, demonstrating continued and growing adoption of Q Inside Safety Technology
DELRAY BEACH, Fla., March 12, 2015 (GLOBE NEWSWIRE) -- VeriTeQ Corporation ("VeriTeQ") (OTC Markets:VTEQ), a provider of implantable medical device identification and radiation dose measurement technologies, and Establishment Labs, S.A. ("EL") announced today that The Hospital Group, the largest provider of cosmetic surgery in the United Kingdom ("UK"), now offers EL's Motiva Implant Matrix® breast implants with VeriTeQ's Q Inside Safety Technology™ to patients choosing to undergo breast augmentation. The Hospital Group operates a network of more than 20 clinics around the UK and Ireland.
Q Inside Safety Technology™ is an FDA cleared micro-transponder technology that acts as an electronic serial number enabling physicians and patients to access a secure, online database to retrieve implant-specific data, such as serial number, manufacturer name, date of manufacture, lot number, volume, size, and other data from the device manufacturer. Q Inside Safety Technology™ may also provide an extra level of protection to the patient in the event of a recall or other safety event.
EL's Motiva Implant Matrix® Ergonomix™, VelvetSurface® PLUS, and SilkSurface® PLUS, all with VeriTeQ's Q Inside Safety Technology, have received CE Mark approval, which enables EL to market its Motiva Implant Matrix® breast implants to patients in 28 countries in the European Union.
"We are very proud that The Hospital Group, the premier provider of cosmetic surgery in the UK, has chosen our latest generation of Motiva implants with Q Inside Safety Technology™," said Juan Jose Chacon-Quiros, CEO of EL. "Women opting for breast enhancement in the UK and other countries now have full control over the origin and safety of their implants over the life of the devices."
"Thousands of women have already selected EL's Motiva Implant Matrix breast implants with our Q Inside Safety Technology," stated Scott R. Silverman, Chairman and CEO of VeriTeQ. "We believe our next generation technology offers women the ability to protect the integrity of their medical devices and ultimately, their health."
VeriTeQ develops innovative, proprietary RFID technologies for implantable medical device identification, and dosimeter technologies for use in radiation therapy treatment. VeriTeQ offers the world's first FDA cleared RFID microchip technology that can be used to identify implantable medical devices, in vivo, on demand, at the point of care. VeriTeQ's dosimeters provide patient safety mechanisms while measuring and recording the dose of radiation delivered to a patient in real time. For more information on VeriTeQ, please visit www.veriteqcorp.com.
Establishment Labs is a global, privately held breast, body and facial aesthetic company with offices in Florida, Costa Rica and Belgium, that designs, develops, manufactures and markets an innovative product portfolio consisting of advanced silicone-filled breast (www.motivaimplants.com) and body shaping implants. Utilizing only the highest quality of medical grade silicones, the CE-marked Motiva Implant Matrix® line is rigorously scrutinized by professional Quality Engineers throughout the entire manufacturing process. All of its products are manufactured in full compliance with ISO and EU requirements, and are certified under the Medical Device Directive 93/42/EEC. For more information on EL, please visit www.establishmentlabs.com.
Statements in this press release that are not purely historical facts, including statements about our beliefs, intentions or future expectations, may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, Section 21E of the Securities Exchange Act of 1934, and as that term is defined in the Private Securities Litigation Reform Act of 1995. Such forward-looking statements consist of any statement other than a recitation of historical fact and can be identified by the use of forward-looking terminology such as "may", "expect", "anticipate", "intend", "estimate" or the negative thereof or other variations thereof or comparable terminology. The reader is cautioned that all forward looking statements involve risks and uncertainties and are subject to change at any time, and that our actual results could differ materially from expected results. These risks and uncertainties include, without limitation, VeriTeQ's ability to continue to raise capital to fund its operations; VeriTeQ's ability to successfully commercialize its Q Inside Safety Technology; as well as other risks or events beyond VeriTeQ's control. Additional information about these and other factors may be described in VeriTeQ's Form 10-K, filed on April 15, 2014, as amended August 19, 2014; and Form 10-Q, filed on November 18, 2014; and future filings with the Securities and Exchange Commission. VeriTeQ undertakes no obligation to update or release any revisions to these forward-looking statements to reflect events or circumstances after the date of this statement or to reflect the occurrence of unanticipated events, except as required by law.
VeriTeQ Allison Tomek, 561-846-7003 email@example.com